2 May 2018 - - Vilnius, Lithuania-based biopharmaceutical CDMO Biotechpharma UAB and Taipei, Taiwan-based vaccine developer TheVax Genetics Vaccine Co., Ltd (6567.TWO) and have entered into a manufacturing agreement to produce Thevax HBV vaccine for first-in-human clinical trials, the companies said.
TheVax Genetics Vaccine Co. is engaged in development of human vaccines.
The company's main products include therapeutic monovalent and multivalent vaccines for the treatment of cervical cancer and precancerous lesions, and therapeutic vaccines for the treatment of Hepatitis B.
Biotechpharma UAB provides fully integrated process development and GMP manufacturing services globally.
The company has extensive experience in the production of new biological entities, having 150 employees at its state-of-the-art facility in Vilnius, Lithuania.